EMA Application withdrawn: Begedina (begelomab) — Adienne S.r.l. S.U.

View source ↗

Summary

EMA withdrew the application for Begedina (begelomab) by Adienne S.r.l. S.U. for graft-versus-host disease/Hematopoietic Stem Cell Transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematopoietic Stem Cell Transplantation

Drugs mentioned

• BEGEDINA

Snippet

Status: Application withdrawn. Therapeutic area: Graft vs Host Disease;Hematopoietic Stem Cell Transplantation. MAH: Adienne S.r.l. S.U.. Decision date: 22/07/2016. Orphan medicine